- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02540044
Supporting Patient Care With Electronic Resource (SuPER) (SuPER)
Supporting Patient Care With Electronic Resource (SuPER): Efficacy of an Online Decision Aid for Patients Considering Biologic Therapy for Rheumatoid Arthritis
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The proposed project aims to improve the process of making evidence-informed treatment decisions by patients with rheumatoid arthritis (RA) and ultimately, empower patient self-management. Current RA treatment emphasizes: 1) the need for early and aggressive treatment, and 2) the use of a Treat-to-Target approach. Patients often struggle with treatment decisions, however, especially when the options have both benefits and risks. To address this challenge, the investigators have developed a new online decision aid called ANSWER-2 (ANimated, Self-serve, WEb-based, Research Tool: Version 2) for RA patients who are considering a biologic or other new therapy. A unique feature of ANSWER-2 is its ability to individualize how treatment options are presented based on the patient's preferences.
Objective: 1) To evaluate the effectiveness of ANSWER-2 in reducing patients' decisional conflict. 2) To assess the extent to which ANSWER-2 improves patients' knowledge about RA medications and confidence in managing their health. 3) To examine the experiences of patients and rheumatologists in using the ANSWER-2.
The investigators will conduct a proof-of-concept randomized controlled trial with 148 patients with RA. Eligible individuals are those: 1) with a diagnosis of RA from a rheumatologist, 2) whose rheumatologists have recommended initiating a biologic or other new therapy or switching to another agent, and 3) who have internet access. The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own within two days. At the end of the session, a one-page summary will be produced to help them discuss their questions, concerns, and preferred choices with their health care providers. The Control Group will receive The Arthritis Society's online education booklet "Arthritis Medications: A Consumer's Guide". Participants will complete the Decisional Conflict Scale (primary outcome) before and after the intervention (ANSWER-2 or booklet). The following secondary outcome measures will be collected at baseline, 1 month and 2 months: 1) Medication Education Impact Questionnaire (MeIQ), and 2) Partners in Health Scale (PHS). In addition, use of healthcare resources will be collected at 2 months. Participants will also be asked about their medication preferences at Month 1, as well as the shared decision making process in their last appointment, (using the 3-item CollaboRATE scale), at Month 1. Participants who received the ANSWER-2 decision aid and their rheumatologists will be invited to participate in an interview about their experience with the patient decision aid. The investigators will use analysis of variance (ANOVA) to compare between the Intervention Group and Control Group, using the baseline measure as a covariate. An iterative content analysis will be conducted for the qualitative interviews.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
British Columbia
-
Richmond, British Columbia, Kanada, V6X2C7
- Rekrutierung
- Arthritis Research Canada
-
Kontakt:
- Jasmina Geldman, MS
- Telefonnummer: 604-207-4007
- E-Mail: jgeldman@arthritisresearch.ca
-
Kontakt:
- Navi Grewal, MS
- Telefonnummer: 604-207-4053
- E-Mail: ngrewal@arthritisresearch.ca
-
Hauptermittler:
- Linda Li, PT,PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- The inclusion criteria are as follows: 1) with a diagnosis of RA from a rheumatologist, 2) whose rheumatologists have recommended initiating a biologic/subsequent entry biologic or switching to another biologic agent, and 3) who have internet access and email.
Exclusion Criteria:
- Patients who do not meet the inclusion criteria.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: ANSWER-2 decision aid
The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days.
At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
|
ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option.
Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
|
Aktiver Komparator: Control Group (TAS Consumer Guide)
The Control Group will receive the online Arthritis Medications: A Consumer's Guide, published by The Arthritis Society.
It contains standard information about biologics, including an introduction of the different biologic options, dosages and side effects.
|
The Arthritis Society Consumer guide pdf.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Decisional Conflict Scale
Zeitfenster: Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1)
|
The Decisional Conflict Scale (short version) measures personal perceptions of uncertainty in choosing options, factors contributing to uncertainty, and effective decision-making.
It is one-dimensional and has 10 questions and three response categories (yes/no/unsure) used to compute one score.
|
Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
MeiQ
Zeitfenster: Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1, and at month 2)
|
The MeiQ consists of 6 subscales and a total of 29 items.
MeiQ was developed and tested in three different samples of patients with rheumatic conditions on their knowledge of medications.
|
Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1, and at month 2)
|
Partners in Health Scale
Zeitfenster: Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1, and at month 2)
|
The Partners in Health Scale is an 11-item measure, designed to assess self-efficacy, knowledge of RA and treatment, and self-management behaviours such as taking medication appropriately and adopting a healthy lifestyle.
|
Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1, and at month 2)
|
Health Resource Utilization
Zeitfenster: Change measure (baseline score compared to after using the ANSWER-2 at month 2)
|
The HRU questionnaire was developed for both self and interviewer administration in people with arthritis and other chronic conditions.
It consists of a series of open-ended questions about individuals' visits to health professionals, use of investigative tests, hospital visits, use of medications, purchases of adaptive aids, and estimable productivity loss incurred by the individual and their caregivers due to the his/her health.
|
Change measure (baseline score compared to after using the ANSWER-2 at month 2)
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
CollaboRATE Scale
Zeitfenster: Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1)
|
a 3-item measure of the shared decision making process
|
Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1)
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Linda Li, PhD, professor
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- H15-02046
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Arthritis, Rheuma
-
CEN BiotechMYEXPRESIONRekrutierungPolyarthritis; RheumatoidFrankreich
-
Centre Hospitalier Universitaire, AmiensUnbekanntMethotrexat | Polyarthritis; RheumatoidFrankreich
-
Chang Gung Memorial HospitalNoch keine RekrutierungArthritis-Knie | Arthritis HüfteTaiwan
-
Centocor, Inc.AbgeschlossenRheumatoide Arthritis, Jugendliche
-
University of Alabama at BirminghamNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) und andere MitarbeiterAbgeschlossen
-
Assistance Publique - Hôpitaux de ParisAbgeschlossenJuvenile idiopathische Arthritis | Arthritis, septisch | Arthritis, nicht näher bezeichnetFrankreich
-
Saint Alphonsus Regional Medical CenterAbgeschlossenArthritis-Knie | Arthritis der HüfteVereinigte Staaten
-
Sunnybrook Health Sciences CentreUniversity Health Network, Toronto; University of TorontoAbgeschlossen
-
AmgenBeendetJuvenile rheumatoide Arthritis
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)AbgeschlossenJuvenile rheumatoide ArthritisVereinigte Staaten
Klinische Studien zur ANSWER-2 decision aid
-
NYU Langone HealthRekrutierung
-
Assistance Publique - Hôpitaux de ParisNational Research Agency, FranceAbgeschlossenRheumatoide Arthritis | Uveitis | Vaskulitis | Diabetes Typ 1 | Morbus Crohn | Myositis | Gesunder Freiwilliger | Spondylitis ankylosans | FMF | Systemischer Lupus erythematodes/Antiphospholipid-Syndrom | Kryopyrin-assoziiertes periodisches Syndrom/TNF-Rezeptor-assoziiertes periodisches Syndrom | Ulzerative... und andere BedingungenFrankreich
-
Steno Diabetes Center CopenhagenRigshospitalet, DenmarkRekrutierungDiabetes mellitus, Typ 2 | Diabetes mellitus, Typ 1 | Hämodialyse | Peritonealdialyse | Chronisches Nierenleiden | DialyseDänemark